Latest Insider Transactions at Kal Vista Pharmaceuticals, Inc. (KALV)
This section provides a real-time view of insider transactions for Kal Vista Pharmaceuticals, Inc. (KALV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of KalVista Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of KalVista Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2025
|
Brian Piekos Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,471
-29.81%
|
$58,123
$13.45 P/Share
|
|
Nov 24
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,940
-2.56%
|
$142,220
$13.45 P/Share
|
|
Nov 24
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,296
-3.86%
|
$68,848
$13.45 P/Share
|
|
Nov 24
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
4,331
-1.9%
|
$56,303
$13.45 P/Share
|
|
Nov 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.52%
|
-
|
|
Nov 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+1.35%
|
-
|
|
Nov 21
2025
|
Brian Piekos Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Nov 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+5.16%
|
-
|
|
Nov 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.52%
|
-
|
|
Nov 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+1.64%
|
-
|
|
Nov 20
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
87,390
+28.34%
|
-
|
|
Nov 18
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,075
-2.38%
|
$43,050
$14.48 P/Share
|
|
Nov 18
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,683
-1.97%
|
$37,562
$14.48 P/Share
|
|
Nov 18
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,466
-1.09%
|
$62,524
$14.48 P/Share
|
|
Nov 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+4.76%
|
-
|
|
Nov 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+2.99%
|
-
|
|
Nov 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,364
+2.24%
|
-
|
|
Nov 12
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,328
-0.83%
|
$36,608
$11.55 P/Share
|
|
Nov 11
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,120
+1.74%
|
-
|
|
Sep 08
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,294
-1.81%
|
$109,410
$15.84 P/Share
|
|
Sep 06
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+3.74%
|
-
|
|
Aug 25
2025
|
Nicole Sweeny Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,480
-4.38%
|
$19,240
$13.42 P/Share
|
|
Aug 25
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,336
-1.87%
|
$30,368
$13.42 P/Share
|
|
Aug 25
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,954
-1.46%
|
$25,402
$13.42 P/Share
|
|
Aug 22
2025
|
Nicole Sweeny Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.9%
|
-
|
|
Aug 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.85%
|
-
|
|
Aug 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+2.28%
|
-
|
|
Aug 22
2025
|
Nicole Sweeny Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,864
-6.08%
|
$24,232
$13.22 P/Share
|
|
Aug 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,942
-2.4%
|
$38,246
$13.22 P/Share
|
|
Aug 22
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,940
-2.75%
|
$142,220
$13.22 P/Share
|
|
Aug 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,362
-1.77%
|
$30,706
$13.22 P/Share
|
|
Aug 21
2025
|
Nicole Sweeny Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+16.94%
|
-
|
|
Aug 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.84%
|
-
|
|
Aug 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+5.52%
|
-
|
|
Aug 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+2.74%
|
-
|
|
Aug 18
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,409
-1.16%
|
$57,317
$13.19 P/Share
|
|
Aug 18
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,939
-2.46%
|
$38,207
$13.19 P/Share
|
|
Aug 18
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,649
-2.0%
|
$34,437
$13.19 P/Share
|
|
Aug 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,362
+2.41%
|
-
|
|
Aug 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,446
+5.12%
|
-
|
|
Aug 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,203
+3.08%
|
-
|
|
Jul 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
32,979
-8.19%
|
$494,685
$15.69 P/Share
|
|
Jul 09
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
30,250
-19.12%
|
$453,750
$15.69 P/Share
|
|
Jul 08
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+17.85%
|
-
|
|
Jul 08
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+27.5%
|
-
|
|
Jun 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,169
-2.22%
|
$100,366
$14.5 P/Share
|
|
Jun 06
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+4.62%
|
-
|
|
May 23
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,926
-1.92%
|
$21,186
$11.31 P/Share
|
|
May 23
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,146
-1.86%
|
$23,606
$11.31 P/Share
|
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.03%
|
-
|